\u2013 Next-Generation CAR T-cell Therapies Suggest High Response Rates and Encouraging Durability in B-Cell Malignancies \u2013<\/i><\/b><\/p>\n
FOSTER CITY, Calif.–(BUSINESS WIRE<\/a>)– This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20251102053147\/en\/<\/a><\/p>\n \n\u201cKite is dedicated to advancing cell therapy as a path to cures, and our data at ASH will reflect meaningful progress toward this goal,\u201d said Cindy Perettie, Executive Vice President of Kite. \u201cTogether with our partner Arcellx, we\u2019ll unveil the updated results from the pivotal Phase 2 iMMagine-1 study. These findings will lay the foundation for our aspiration with anito-cel to deliver a differentiated treatment for relapsed\/refractory multiple myeloma with strong potential for community oncology access and reduced burden on patients and caregivers.\u201d<\/p>\n Anito-cel Data Updates<\/span><\/b><\/p>\n \nKey presentations for anitocabtagene autoleucel (anito-cel) include updated results from the fully enrolled, ongoing iMMagine-1 Phase 2 pivotal study. No delayed neurotoxicities, including no Parkinsonism, no cranial nerve palsies, no Guillain-Barr\u00e9 syndrome, and no immune-mediated enterocolitis, have been observed to date.<\/p>\n Data on Next-Generation Pipeline<\/span><\/b><\/p>\n \nKite will also share new data on its next-generation bicistronic autologous CAR T-cell therapies, KITE-363 and KITE-753.<\/b> These therapies are designed to target two antigens (CD19 and CD20) found on cancer cells and use two co-stimulatory domains (CD28 and 4-1 BB) to help the immune system fight cancer more effectively. This dual-targeting approach may lower the chance of the cancer escaping treatment and could also improve safety, making it possible to treat patients outside of a hospital setting.<\/p>\n Survival Outcomes with Yescarta<\/span><\/b>\u00ae<\/sup> Based on ASCT Eligibility<\/span><\/b><\/p>\n \nA key presentation for Yescarta\u00ae<\/sup> (axicabtagene ciloleucel) includes a joint analysis of 4-year follow-up data from ZUMA-7, which evaluated Yescarta as a second-line therapy in patients with relapsed\/refractory (R\/R) large B-cell lymphoma (LBCL) eligible for autologous stem-cell transplant (ASCT), alongside 2-year follow-up data from ALYCANTE that evaluated patients who were ASCT ineligible. Efficacy, safety, and health-related quality of life patterns were observed to be consistent across both ZUMA-7 and ALYCANTE populations, supporting the use of Yescarta regardless of transplant eligibility and effectively broadening eligibility to this potentially curative, one-time treatment.<\/p>\n \nDates and times are listed in ET for the following accepted abstracts and presentations:<\/p>\n
\nGilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 21 abstracts, including 5 oral presentations, during the 67th American Society of Hematology (ASH) Annual Meeting and Exposition (December 6-9). These data showcase Kite\u2019s continued progress in transforming blood cancer care and expanding the reach and impact of CAR T-cell therapy.<\/p>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20251102053147\/en\/778437\/3\/GCP_Primarylarge_1.jpg\")
<\/td>\n<\/tr>\n![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20251102053147\/en\/836069\/3\/NEW_KITE_COLOR_LOGO.jpg\"){kind=logo}
<\/td>\n<\/tr>\n